Born to survive: how cancer cells resist CAR T cell therapy
Authors:
Open Access
- 22 November 2021
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-12
Abstract
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.Keywords
This publication has 106 references indexed in Scilit:
- CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28−CD8+ T CellsThe Journal of Immunology, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioningBlood, 2012
- Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumorsJournal of Clinical Investigation, 2012
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2008
- T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejectionNature Medicine, 2007
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006
- Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cellsOncogene, 2003
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003